CytRx Delays Nasdaq Delisting, Changes Subsidiary Name

CytRx said this week that it has postponed the delisting of its stock from the Nasdaq Small Cap Market, stemming from the company’s failure to file its 10-K annual report for 2003, by requesting a hearing with the Nasdaq Qualifications Panel.

That hearing is set for May 13, said CytRx.

The company previously said it received a letter from the Nasdaq on April 19 warning of the possibility of delisting. Pending that hearing, CytRx’s stock will continue to trade under the symbol “CYTRE.”